Alloy Therapeutics, a Boston, MA-based biotechnology ecosystem company, raised $42M in Series D funding.
The round was led by 8VC and Mubadala Capital with participation from Thiel Capital, Presight Capital, Founders Fund.
The company intends to use the funds to continue to invest in expanded offerings across all six of its modalities cited below.
Led by Chief Executive Officer and Founder Errik Anderson, Alloy Therapeutics is a biotechnology ecosystem company empowering the global scientific community to make medicines together. Through a community of partners across academia, biotech, and the largest biopharma, Alloy democratizes access to pre-competitive tools, technologies, services, and company creation capabilities that are foundational for discovering and developing therapeutic biologics across six modalities, including antibodies, TCRs, genetic medicines, peptides, cell therapies, and drug delivery.
The company launched in 2017 with ATX-Gx™, a suite of transgenic mouse strains for human antibody discovery that was originally in-licensed from a major pharma company and made broadly available to the drug discovery ecosystem by Alloy, with open access to newly introduced strains. Through its DeepImmune™ Antibody Discovery services, Alloy helps partners find the best therapeutic antibody candidates against targets of interest, by deploying a bespoke blend of its proprietary in vivo, in vitro, and in silico technologies and workflows. In 2022, the company launched Keyway™ TCR Discovery as its second fully integrated technology and services offering for the discovery of therapeutic engineered TCRs and TCR mimics.
Since Series C fundraise in March 2021, Alloy has expanded from its foundational antibody discovery technologies and discovery services into T-cell receptors (TCRs), with the launch of its Keyway TCR Discovery division, and genetic medicines through its collaboration with Dr. Sudhir Agrawal, the inventor of gapmer technology. The company has further expanded with three new research sites, in Basel, CH; Athens, GA; and San Francisco, CA.
FinSMEs
04/10/2022